News

The EUTOPS team’s new paper evaluates circulating cell-free DNA methylation markers that could be used to improve diagnosis and earlier detection of ovarian cancers. The data suggest that analysis of cell-free DNA methylation, alone or combined with the existing CA125 marker, could help to detect ovarian cancers earlier and may reduce mortality from the disease.

A new paper from the EUTOPS team has been published in Precision Oncology highlighting the dynamic interplay between genetics and nonheritable factors captured on the epigenome, varying across different sample types, and indicating breast cancer risk.

Martin Widschwendter, Professor of Oncology and Prevention at the University of Innsbruck, has been awarded Proof of Concept funding from the European Research Council (ERC) for his pioneering work in preventive medicine. The new project is based on his ERC Advanced Grant and is intended to further exploit his work in cancer prevention.

Read our new publication in Cell in collaboration with the international Biomarkers of Aging Consortium.

EUTOPS postdoctoral researcher Chiara Herzog has received the Ernst Brandl Prize of €4,000 for her work on the development and validation of a novel epigenetic test – the WID-qEC test – for the early detection of endometrial cancer. Chiara is an integral member of the EUTOPS team, working on computational aspects of epigenetics in cancer development and prevention and in ageing research.

A new publication from Professor Martin Widschwendter and the EUTOPS team in the International Journal of Cancer describes the development of cervical cancer as a result of Human Papilloma Virus (HPV) infection.

The EUTOPS team presents four publications demonstrating that DNA methylation signature assessment using methylation array analysis in cervical screening samples detects and likely predicts the risk for all four major women’s cancers: breast, ovarian, womb and cervical cancer.

A new publication from Professor Martin Widschwendter and the EUTOPS team in Genome Medicine describes a new molecular test that can identify 55% of those with a normal cervical smear result who will go on to develop advanced cell changes or cancer within 4 years.